Papers 4,811
1 page of 482 pages (4,811 results)
#1Julio Delgado (EMA: European Medicines Agency)H-Index: 45
#2Malgorzata Zienowicz (EMA: European Medicines Agency)H-Index: 1
Last. Francesco Pignatti (EMA: European Medicines Agency)H-Index: 23
view all 7 authors...
Isatuximab is a monoclonal antibody that binds to the human CD38 antigen. On 30 May 2020, a marketing authorization valid through the European Union (EU) was issued for isatuximab in combination with pomalidomide and dexamethasone (IsaPd) for the treatment of adult patients with relapsed and refractory (RR) multiple myeloma (MM). The recommended dose of isatuximab was 10 mg/kg, administered IV weekly at cycle 1 and then biweekly in subsequent 28-day cycles. Isatuximab was evaluated in a phase 3,...
#1Ki-Tae Hwang (SMG: Seoul Metropolitan Government)H-Index: 4
#2Young Jin Suh (Catholic University of Korea)H-Index: 33
Last. Junwon Min (DKU: Dankook University)H-Index: 3
view all 8 authors...
BACKGROUND We investigated the prognostic and predictive roles of the hormone receptor (HRc) subtype in patients with ductal carcinoma in situ (DCIS). We focused on identifying the roles of the progesterone receptor (PR) independent of estrogen receptor (ER) status. METHODS Nationwide data of 12,508 female patients diagnosed with DCIS with a mean follow-up period of 60.7 months were analyzed. HRc subtypes were classified as ER-/PR-, ER-/PR+, ER+/PR-, and ER+/PR+ based on ER and PR statuses. The ...
#1Khanh T. Do (Harvard University)H-Index: 21
#2Laura Quan Man Chow (UW: University of Washington)H-Index: 39
Last. Amy Weise (WSU: Wayne State University)H-Index: 17
view all 16 authors...
LESSONS LEARNED Inhibition of glycoprotein fucosylation, as monotherapy and in combination with immune checkpoint blockade, is a promising therapeutic strategy for treating a broad range of cancers. In this first-in-human, first-in-class, phase I study in advanced solid tumors, SGN-2FF demonstrated dose-proportional pharmacokinetics, evidence of pharmacodynamic target inhibition of glycoprotein fucosylation, and preliminary antitumor activity. SGN-2FF was associated with thromboembolic events th...
#1Ting Bao (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 19
#2Raymond E. Baser (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 27
Last. W Iris Zhi (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 2
view all 9 authors...
Background null Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating adverse effect of neurotoxic chemotherapy that significantly worsens cancer survivors' quality of life. null Materials and methods null Solid tumor survivors with persistent moderate-to-severe CIPN defined as numbness, tingling, or pain rated ≥4 on an 11-point numeric rating scale (NRS) were randomized in a 1:1:1 ratio to eight weeks of real acupuncture (RA) versus sham acupuncture (SA) versus usual care ...
#1John Zalcberg (Monash University)H-Index: 72
#2Michael Heinrich (OHSU: Oregon Health & Science University)H-Index: 133
Last. Gina Z. D'Amato (UM: University of Miami)H-Index: 14
view all 20 authors...
BACKGROUND: Ripretinib 150 mg once daily (QD) is indicated for advanced gastrointestinal stromal tumors (GISTs) as at least fourth-line therapy. In INVICTUS, ripretinib intrapatient dose escalation (IPDE) to 150 mg b.i.d. was allowed after progressive disease (PD) on 150 mg QD by blinded independent central review using modified RECIST 1.1. We report the efficacy and safety of ripretinib IPDE to 150 mg b.i.d. after PD among patients randomized to ripretinib 150 mg QD in the INVICTUS study. MATER...
#1Nishita Tripathi (HCI: Huntsman Cancer Institute)
#2Neeraj Agarwal (HCI: Huntsman Cancer Institute)H-Index: 63
Last. Abhishek Tripathi (OUHSC: University of Oklahoma Health Sciences Center)H-Index: 4
view all 3 authors...
#1Yizhuo Kelly Gao (University of Toronto)H-Index: 1
#2Markus Kuksis (Queen's University)H-Index: 4
Last. Hany Soliman (University of Toronto)H-Index: 18
view all 11 authors...
BACKGROUND Breast cancer is the most common cancer among women worldwide and the second leading cause of brain metastases (BrM). We assessed the treatment patterns and outcomes of women treated for breast cancer BrM at our institution in the modern era of stereotactic radiosurgery (SRS). MATERIALS AND METHODS We conducted a retrospective analysis of women (≥18 years of age) with metastatic breast cancer who were treated with surgery, whole brain radiotherapy (WBRT), or SRS to the brain at the Su...
#1Ying Zheng (Merck Serono)H-Index: 8
#2Ruth Kim (Pfizer)H-Index: 2
Last. Saby George (RPCI: Roswell Park Cancer Institute)H-Index: 30
view all 8 authors...
BACKGROUND With increased use of immune checkpoint inhibitors (ICIs) among patients with cancer, there is substantial interest in understanding clinical and economic outcomes and management of immune-related adverse events (irAEs). PATIENTS, MATERIALS, AND METHODS A retrospective study was conducted using Premier Healthcare Database, a U.S. national hospital discharge database, from March 1, 2015, through December 31, 2017. The database comprises more than 880 million inpatient and hospital-base...
#1Leonardo Potenza (University of Modena and Reggio Emilia)H-Index: 28
#2Mario Luppi (University of Modena and Reggio Emilia)H-Index: 66
Last. Elena BandieriH-Index: 10
view all 5 authors...
#1Joerg Trojan (Goethe University Frankfurt)H-Index: 26
#2Sebastian Stintzing (Charité - University Medicine Berlin)H-Index: 37
Last. Ivan Jelas (Charité - University Medicine Berlin)H-Index: 3
view all 7 authors...
BACKGROUND Patients with colorectal carcinoma and high-grade microsatellite instability (MSI-H) or deficiency in mismatch repair (dMMR) exceptionally respond to immune checkpoint inhibitors (ICIs). ICIs are more active in treatment-naive patients than in patients with refractory MSI-H/dMMR metastatic colorectal cancer and even more active in patients with locally advanced tumors. MATERIAL AND METHODS A 33-year-old male patient with Lynch syndrome was diagnosed with a locally advanced rectal canc...
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.